Published: 3/1/2023 8:14:07 AM

Inhalation Sciences Q4 2022: In line with our expectations - Redeye

Redeye provides an update in relation to ISAB’s Q4 2022 report. Full-year sales came in at SEK12.2m (SEK9.4m) and EBIT at SEK-12.0m (SEK-16.6m). We have chosen to make some changes in our model, mainly changes in sales and OPEX, and included an equity issue during 2023. This results in a new fair value range.

Link to the analysis

Read more about Inhalation Sciences Sweden AB